Robotic surgery that lets surgeons feel tissue resistance at their fingertips may reduce vocal cord dysfunction in patients with esophageal cancer, according to a new study.

A research team led by Professor Seong Yong Park of the Thoracic and Esophageal Surgery Department and Professor Danbee Kang of the Center for Clinical Epidemiology at Samsung Medical Center analyzed 163 patients with esophageal squamous cell carcinoma who underwent robotic esophagectomy between December 2024 and July 2026. The findings were published in a recent issue of Journal of Robotic Surgery, an international journal in the field of robotic surgery.

Esophageal cancer surgery has evolved from open chest surgery to minimally invasive procedures using thoracoscopy and robotic systems, reducing the physical burden on patients. However, robotic surgery had its limitations. Surgeons could not directly feel the force they applied to tissue and had to estimate its strength from the screen.

Squamous cell carcinoma of the esophagus spreads to the lymph nodes around the nerves that control the vocal cords in up to 50% of cases. Surgery therefore requires precision: enough lymph nodes must be removed while the nerves are protected. If surrounding tissue is pulled too forcefully during lymph node removal, the nerves can be damaged. This can cause a hoarse voice or difficulty swallowing, and it also raises the risk of aspiration pneumonia, which occurs when food enters the airway.

Recently, next-generation robotic systems incorporating technology that addresses these limitations have been introduced. Surgeons can now sense the resistance of tissue through the console handles and adjust the force they apply. To determine whether this technology reduces postoperative vocal cord dysfunction, the team compared 126 patients who underwent surgery with the existing system (da Vinci Xi) and 37 patients who underwent surgery with the next-generation system (da Vinci 5).

The results showed that the proportion of patients whose vocal cord movement decreased or was paralyzed after surgery was 13.5% in the next-generation system group. This was less than half the rate of 33.3% in the existing system group. The median length of hospital stay was 11 days in the next-generation system group, two days shorter than the 13 days in the existing system group.

There were no statistically significant differences between the two groups in operative time, blood loss, or the number of lymph nodes removed. Given the similar number of lymph nodes removed, the research team noted that handling the tissue around the nerves more gently may have contributed to the reduction in vocal cord dysfunction.


Professor Park said, “Esophageal cancer surgery has moved beyond reducing incision size and has now reached a stage where we can recreate the sense of force, a limitation of robotic surgery until now.” He added, “We hope this will help not only treat the cancer but also allow patients to keep speaking in their own voice in their daily lives after treatment.”

Meanwhile, the Thoracic and Esophageal Surgery Department at Samsung Medical Center introduced a da Vinci robot dedicated to lung and esophageal surgery in 2023 and surpassed 1,000 cumulative robotic surgeries in 2025. In the same year, the department was designated an Epicenter, a training center for robotic surgery designated by Intuitive Surgical.


Paper Information

Force feedback and vocal cord dysfunction after robotic esophagectomy: a comparison of the da Vinci 5 and Xi systems

Journal of Robotic Surgery (IF 4.2)



Authors:

Co-corresponding author: Seong Yong Park, Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center

Co-corresponding author: Danbee Kang, Center for Clinical Epidemiology, Samsung Medical Center